Display options
Cite
Juge PA, Gazal S, Constantin A, et al. Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open. 2017;3(2):e000448doi: 10.1136/rmdopen-2017-000448.
Juge, P. A., Gazal, S., Constantin, A., Mariette, X., Combe, B., Tebib, J., Dougados, M., Sibilia, J., Le Loet, X., & Dieudé, P. (2017). Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD open, 3(2), e000448. https://doi.org/10.1136/rmdopen-2017-000448
Juge, Pierre-Antoine, et al. "Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis." RMD open vol. 3,2 (2017): e000448. doi: https://doi.org/10.1136/rmdopen-2017-000448
Juge PA, Gazal S, Constantin A, Mariette X, Combe B, Tebib J, Dougados M, Sibilia J, Le Loet X, Dieudé P. Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis. RMD Open. 2017 Sep 28;3(2):e000448. doi: 10.1136/rmdopen-2017-000448. eCollection 2017. PMID: 29071117; PMCID: PMC5640092.
Copy Download .nbib Format: NLM
Share it on

RMD Open. 2017 Sep 28;3(2):e000448. doi: 10.1136/rmdopen-2017-000448. eCollection 2017.

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis.

RMD open

Pierre-Antoine Juge, Steven Gazal, Arnaud Constantin, Xavier Mariette, Bernard Combe, Jacques Tebib, Maxime Dougados, Jean Sibilia, Xavier Le Loet, Philippe Dieudé

Affiliations

  1. Department of Rheumatology, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Université Paris Diderot, Paris, France.
  2. Plateforme de Génomique Constitutionnelle, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, Université Paris Diderot, Paris, France.
  3. UMR 1027, INSERM, Toulouse III University, Toulouse, France.
  4. Department of Rheumatology, Hôpital Purpan, CHU Toulouse, Toulouse, France.
  5. Department of Rheumatology, Université Paris-Sud, Assistance Publique-Hôpitaux de Paris, Paris, France.
  6. INSERM U1184, Université Paris-Sud, Paris, France.
  7. Department of Rheumatology, Service d'Immuno-Rhumatologie, Montpellier, France.
  8. Department of Rheumatology, Hôpital Lyon-sud, Pierre-Bénite, France.
  9. Department of Rheumatology, Université Paris Descartes, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.
  10. INSERM U1153, PRES Sorbonne Paris-Cité, Paris, France.
  11. Centre de Référence des Maladies Auto-immune Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
  12. Department of Rheumatology, Rouen University Hospital, Rouen, France.
  13. INSERM U699, Université de Paris Diderot, PRES Sorbonne Paris-Cité, Paris, France.

PMID: 29071117 PMCID: PMC5640092 DOI: 10.1136/rmdopen-2017-000448

Abstract

BACKGROUND: The type 1 interferon (IFN) pathway has been identified to potentially affect the response to rituximab (RTX) for rheumatoid arthritis (RA), which suggests the contribution of type 1 IFN pathway genes such as IFN regulatory factor 5 and 7 (

METHODS: Logistic regression analysis with a stepwise multivariate model adjusted for sex, age and DAS28-CRP (Disease Activity Score in 28 joints with C reactive protein) in 115 patients from the SMART randomised studywas used to analyse the association between the candidate variants and W24 EULAR response. Because the variant

RESULTS: The combination of

CONCLUSION: Our results support the contribution of the

Keywords: gene polymorphism; pharmacogenetics; rheumatoid arthritis

Conflict of interest statement

Competing interests: PD is supported by an unrestricted grant from ROCHE.

References

  1. Genes Immun. 2009 Jul;10(5):487-94 - PubMed
  2. Ann Rheum Dis. 2014 Oct;73(10 ):1840-3 - PubMed
  3. Ann Rheum Dis. 2011 Jun;70(6):1153-9 - PubMed
  4. Ann Rheum Dis. 2014 Aug;73(8):1508-14 - PubMed
  5. N Engl J Med. 2004 Jun 17;350(25):2572-81 - PubMed
  6. Blood. 2004 Feb 15;103(4):1376-82 - PubMed
  7. Lancet. 2009 Feb 21;373(9664):659-72 - PubMed
  8. Nature. 2014 Feb 20;506(7488):376-81 - PubMed
  9. Arthritis Rheum. 2010 Dec;62(12):3607-14 - PubMed
  10. Ann Rheum Dis. 2011 Jan;70(1):117-21 - PubMed
  11. Arthritis Rheum. 1998 Oct;41(10):1845-50 - PubMed
  12. Nat Immunol. 2006 May;7(5):498-506 - PubMed
  13. Arthritis Res Ther. 2009;11(3):115 - PubMed
  14. Scand J Rheumatol. 2007 Sep-Oct;36(5):365-72 - PubMed
  15. Ann Rheum Dis. 2007 Aug;66(8):1008-14 - PubMed
  16. Rheumatology (Oxford). 2008 Sep;47(9):1311-6 - PubMed
  17. Rheumatology (Oxford). 2013 Apr;52(4):636-41 - PubMed
  18. Arthritis Rheum. 2011 Mar;63(3):749-54 - PubMed
  19. Arthritis Rheum. 2009 Jul;60(7):1991-7 - PubMed

Publication Types